Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples